Below are the most recent publications written about "Adenocarcinoma, Follicular" by people in Profiles.
-
Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC, Singer MC, Stack BC, Wirth LJ, Wong RJ, Randolph GW. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024 03 01; 150(3):265-272.
-
Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019 Mar 04; 19(1):196.
-
Topf MC, Wang ZX, Tuluc M, Pribitkin EA. TERT, HRAS, and EIF1AX Mutations in a Patient with Follicular Adenoma. Thyroid. 2018 06; 28(6):815-817.
-
Witt RL. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice. Del Med J. 2016 Dec; 88(12):366-372.
-
Wei S, LiVolsi VA, Brose MS, Montone KT, Morrissette JJ, Baloch ZW. STK11 Mutation Identified in Thyroid Carcinoma. Endocr Pathol. 2016 Mar; 27(1):65-9.
-
Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer. 2015 12; 22(6):877-87.
-
Tuluc M, Solomides C. Thyroid cytology. Otolaryngol Clin North Am. 2014 Aug; 47(4):475-89.
-
Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 2013 Apr; 123(4):1059-64.
-
Brose MS. In search of a real "targeted" therapy for thyroid cancer. Clin Cancer Res. 2012 Apr 01; 18(7):1827-9.
-
Jing X, Knoepp SM, Roh MH, Hookim K, Placido J, Davenport R, Rasche R, Michael CW. Group consensus review minimizes the diagnosis of "follicular lesion of undetermined significance" and improves cytohistologic concordance. Diagn Cytopathol. 2012 Dec; 40(12):1037-42.